News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fuzheng Huayu (FZHY) Completed Phase 2 Clinical Trial for Treatment of Liver Fibrosis in Patients With Chronic Hepatitis C


11/5/2013 9:59:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WASHINGTON--(BUSINESS WIRE)--Shanghai Sundise Traditional Chinese Medicine Co. Ltd released its multi-center, double-blinded, placebo-controlled clinical phase II trial results at a satellite symposium during the 2013 annual meeting of the American Association for the Study of Liver Diseases (AASLD®). The results indicate that in chronic hepatitis C patients with moderate to severe fibrosis Fuzheng Huayu tablet (FZHY) is safe, well tolerated and tended to stabilize and improve liver fibrosis, making FZHY the first traditional Chinese medicine compound to complete such clinical studies in the treatment of liver diseases.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES